Author

Alyssa Oplt

Washington University in St. LouisORCID 0000-0002-9597-9252Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Andrea R. HagemanniD· 1 shared Angela M. SchabiD· 1 shared Brooke E. SandersiD· 1 shared Carmen Sandoval· 1 shared Carolyn Kay McCourtiD· 1 shared David Gardner MutchiD· 1 shared Dineo KhabeleiD· 1 shared Eden Gallup· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrea R. HagemannORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Targeting the COP9 signalosome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanisms

Elena Lomonosova, Megan Loeb, Kevin Rodriguez, Lilian N. van Biljon, Joshua D. Brill, Angela M. Schab, Margaret Minett, Jaeden Barron, Maya Bittner, Jiyoung Park, Rebecca Drexler, Carmen Sandoval, Alyssa Oplt, Eden Gallup, Prasanth Thuthika, , Mary Margaret Mullen

The paper identifies COPS5 as a therapeutic target for overcoming platinum resistance in ovarian cancer by inhibiting nucleotide excision repair and interstrand crosslink repair.

bioRxiv · Aug 4, 2025 · PreprintCancer Biology